Blueprint Medicines Corporation

69.72-1.26-1.78%Vol 969.35K1Y Perf -25.46%
Aug 11th, 2022 16:00 DELAYED
BID62.00 ASK80.07
Open71.15 Previous Close70.98
Pre-Market- After-Market69.51
 - -  -0.21 -0.30%
Target Price
86.46 
Analyst Rating
Moderate Buy 2.08
Potential %
24.01 
Finscreener Ranking
★★★★     52.74
Insiders Trans % 3/6/12 mo.
-100/-95/-98 
Value Ranking
★★★+     52.75
Insiders Value % 3/6/12 mo.
-100/-93/-98 
Growth Ranking
★★★★+     61.87
Insiders Shares Cnt. % 3/6/12 mo.
-100/-93/-97 
Income Ranking
 —    -
Price Range Ratio 52W %
35.30 
Earnings Rating
Strong Sell
Market Cap4.16B 
Earnings Date
2nd Aug 2022
Alpha0.00 Standard Deviation0.13
Beta0.98 

Today's Price Range

69.0971.88

52W Range

43.46117.86

5 Year PE Ratio Range

-11.4022.80

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
2.32%
1 Month
26.51%
3 Months
29.04%
6 Months
-14.90%
1 Year
-25.46%
3 Years
-21.75%
5 Years
51.20%
10 Years
-

TickerPriceChg.Chg.%
BPMC69.72-1.2600-1.78
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
89.60
-292.70
-289.80
-400.30
41.08
RevenueValueIndustryS&P 500US Markets
193.94M
3.26
70.69
75.52
Earnings HistoryEstimateReportedSurprise %
Q02 2022-2.23-2.68-20.18
Q01 2022-1.79-1.790.00
Q04 2021-0.71-0.99-39.44
Q03 2021-1.69-2.00-18.34
Q02 2021-1.77-1.86-5.08
Q01 2021-1.80-1.724.44
Q04 2020-1.57-1.532.55
Q03 20206.4911.1671.96
Earnings Per EndEstimateRevision %Trend
6/2022 QR-2.19-19.02Negative
9/2022 QR-1.3926.06Positive
12/2022 FY-7.590.39Positive
12/2023 FY-7.15-21.60Negative
Next Report Date-
Estimated EPS Next Report-2.23
Estimates Count10
EPS Growth Next 5 Years %34.00
Volume Overview
Volume969.35K
Shares Outstanding59.72K
Shares Float59.26M
Trades Count12.53K
Dollar Volume67.84M
Avg. Volume828.20K
Avg. Weekly Volume970.93K
Avg. Monthly Volume732.70K
Avg. Quarterly Volume780.98K

Blueprint Medicines Corporation (NASDAQ: BPMC) stock closed at 69.72 per share at the end of the most recent trading day (a -1.78% change compared to the prior day closing price) with a volume of 969.35K shares and market capitalization of 4.16B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 429 people. Blueprint Medicines Corporation CEO is Jeffrey W. Albers.

The one-year performance of Blueprint Medicines Corporation stock is -25.46%, while year-to-date (YTD) performance is -34.91%. BPMC stock has a five-year performance of 51.2%. Its 52-week range is between 43.46 and 117.86, which gives BPMC stock a 52-week price range ratio of 35.30%

Blueprint Medicines Corporation currently has a PE ratio of -4.80, a price-to-book (PB) ratio of 3.62, a price-to-sale (PS) ratio of 16.11, a price to cashflow ratio of 16.20, a PEG ratio of 2.32, a ROA of -48.57%, a ROC of -52.47% and a ROE of -59.03%. The company’s profit margin is 41.08%, its EBITDA margin is -289.80%, and its revenue ttm is $193.94 Million , which makes it $3.26 revenue per share.

Of the last four earnings reports from Blueprint Medicines Corporation, there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-2.23 for the next earnings report. Blueprint Medicines Corporation’s next earnings report date is -.

The consensus rating of Wall Street analysts for Blueprint Medicines Corporation is Moderate Buy (2.08), with a target price of $86.46, which is +24.01% compared to the current price. The earnings rating for Blueprint Medicines Corporation stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Blueprint Medicines Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Blueprint Medicines Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 8.11, ATR14 : 3.85, CCI20 : 128.48, Chaikin Money Flow : 0.19, MACD : 4.16, Money Flow Index : 61.11, ROC : 37.60, RSI : 54.91, STOCH (14,3) : 90.26, STOCH RSI : 0.81, UO : 70.76, Williams %R : -9.74), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Blueprint Medicines Corporation in the last 12-months were: Ariel Hurley (Option Excercise at a value of $41 076), Ariel Hurley (Sold 7 856 shares of value $666 875 ), Becker Hewes (Option Excercise at a value of $676 178), Becker Hewes (Sold 20 932 shares of value $1 810 348 ), Christina Rossi (Sold 2 244 shares of value $130 986 ), Christopher K. Murray (Sold 6 568 shares of value $406 055 ), Debra Durso-Bumpus (Option Excercise at a value of $182 455), Debra Durso-Bumpus (Sold 8 563 shares of value $827 154 ), Fouad Namouni (Sold 4 288 shares of value $377 032 ), George D. Demetri (Sold 10 shares of value $586 ), Jeffrey W. Albers (Option Excercise at a value of $2 189 040), Jeffrey W. Albers (Sold 235 210 shares of value $19 357 504 ), Kathryn Haviland (Option Excercise at a value of $72 100), Kathryn Haviland (Sold 4 767 shares of value $360 713 ), Mark Alan Goldberg (Buy at a value of $299 900), Michael Landsittel (Sold 2 375 shares of value $138 869 ), Nicholas Lydon (Option Excercise at a value of $213 053), Percy H. Carter (Sold 1 908 shares of value $114 022 ), Tracey McCain (Option Excercise at a value of $992 600), Tracey McCain (Sold 37 714 shares of value $3 919 968 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (61.54 %)
6 (54.55 %)
5 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (23.08 %)
3 (27.27 %)
5 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
2 (15.38 %)
2 (18.18 %)
0 (0.00 %)
Summary RatingModerate Buy
2.08
Moderate Buy
2.27
Moderate Buy
2.00

Blueprint Medicines Corporation

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

CEO: Jeffrey W. Albers

Telephone: +1 617 374-7580

Address: 45 Sidney Street, Cambridge 02139, MA, US

Number of employees: 429

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

54%46%

Bearish Bullish

57%43%

Bearish Bullish

58%42%

TipRanks News for BPMC

Thu, 07 Jul 2022 16:25 GMT Blueprint Medicines (BPMC) Gets a Buy Rating from JMP Securities

- TipRanks. All rights reserved.

Tue, 05 Jul 2022 02:05 GMT Blueprint Medicines (BPMC) Gets a Buy Rating from Stifel Nicolaus

- TipRanks. All rights reserved.

Mon, 04 Jul 2022 02:49 GMT Blueprint Medicines (BPMC) Gets a Buy Rating from Robert W. Baird

- TipRanks. All rights reserved.

Fri, 01 Jul 2022 12:36 GMT Blueprint Medicines (BPMC) Gets a Hold Rating from SVB Securities

- TipRanks. All rights reserved.

Mon, 13 Jun 2022 12:30 GMT Analysts Offer Insights on Healthcare Companies: Blueprint Medicines (BPMC) and Crispr Therapeutics AG (CRSP)

- TipRanks. All rights reserved.

Fri, 10 Jun 2022 10:15 GMT Analysts Conflicted on These Healthcare Names: Blueprint Medicines (BPMC) and IMARA (IMRA)

- TipRanks. All rights reserved.

Mon, 11 Apr 2022 04:20 GMT Blueprint Medicines (BPMC) Receives a Buy from JMP Securities

- TipRanks. All rights reserved.

Tue, 15 Feb 2022 09:31 GMT Blueprint Medicines (BPMC) Receives a Buy from Leerink Partners

- TipRanks. All rights reserved.

News

Stocktwits